MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562623 | Name: SecinH3
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SecinH3 is a cytohesin antagonist.

Chemical Structure

SecinH3
SecinH3
CAS#853625-60-2

Theoretical Analysis

MedKoo Cat#: 562623

Name: SecinH3

CAS#: 853625-60-2

Chemical Formula: C24H20N4O4S

Exact Mass: 460.1205

Molecular Weight: 460.50

Elemental Analysis: C, 62.60; H, 4.38; N, 12.17; O, 13.90; S, 6.96

Price and Availability

Size Price Availability Quantity
5mg USD 270.00
10mg USD 450.00
25mg USD 840.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SecinH3; Secin-H3; Secin H3;
IUPAC/Chemical Name
N-[4-[5-(1,3-Benzodioxol-5-yl)-3-methoxy-1H-1,2,4-triazol-1-yl]phenyl]-2-(phenylthio)acetamide
InChi Key
QPGYAMIHXLCFTJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H20N4O4S/c1-30-24-26-23(16-7-12-20-21(13-16)32-15-31-20)28(27-24)18-10-8-17(9-11-18)25-22(29)14-33-19-5-3-2-4-6-19/h2-13H,14-15H2,1H3,(H,25,29)
SMILES Code
O=C(NC1=CC=C(N2N=C(OC)N=C2C3=CC=C(OCO4)C4=C3)C=C1)CSC5=CC=CC=C5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SecinH3 is an antagonist of cytohesins with IC50s of 5.4 μM, 2.4 μM, 5.4 μM, 5.6 μM, 5.6 μM and 65 μM for hCyh1, hCyh2, mCyh3, hCyh3, drosophila steppke and yGea2-S7, respectively.
In vitro activity:
SecinH3 could be considered a promising candidate as a therapeutic agent of ALS because of its neuroprotective effects against the transactivating response region DNA binding protein 43 p.Q331K mutation (TDP-43 Q331K). SecinH3 attenuated TDP-43 Q331K -induced neuronal toxicity by suppressing ER stress-mediated apoptosis and enhancing autophagic flux. Reference: IUBMB Life. 2019 Feb;71(2):192-199. https://pubmed.ncbi.nlm.nih.gov/30376609/
In vivo activity:
In a rat model of sepsis, SecinH3 relieved lung injury induced by sepsis. After being treated by SecinH3, Pa/O2 was increased, while Pa/CO2 was decreased with the action of SecinH3, indicating that SecinH3 attenuated lung injury. SecinH3 might inhibit the cytohesins and then inhibit the phosphorylation of EGFR. Reference: Asian Pac J Trop Med. 2015 Dec;8(12):1049-1054. https://pubmed.ncbi.nlm.nih.gov/26706678/
Solvent mg/mL mM
Solubility
DMSO 130.0 282.30
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 460.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ren WX, Guo H, Lin SY, Chen SY, Long YY, Xu LY, Wu D, Cao YL, Qu J, Yang BL, Xu HP, Li H, Yu YL, Zhang AY, Wang S, Zhang YC, Zhou KS, Chen ZC, Li QB. Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199. Acta Pharmacol Sin. 2023 Aug 29. doi: 10.1038/s41401-023-01142-2. Epub ahead of print. PMID: 37644132. 2. Hu W, Liu X, Wang S, Sun G, Zhao R, Lu H. SecinH3 Attenuates TDP-43 p.Q331K-Induced Neuronal Toxicity by Suppressing Endoplasmic Reticulum Stress and Enhancing Autophagic Flux. IUBMB Life. 2019 Feb;71(2):192-199. doi: 10.1002/iub.1951. Epub 2018 Oct 30. PMID: 30376609. 3. Dong Y, Song K, Wang P, Guo J, Kang H, Tan X, Zhu B, Peng R, Zhu M, Yu K, Guo Q, Guan H, Li F. Blocking the cytohesin-2/ARF1 axis by SecinH3 ameliorates osteoclast-induced bone loss via attenuating JNK-mediated IRE1 endoribonuclease activity. Pharmacol Res. 2022 Nov;185:106513. doi: 10.1016/j.phrs.2022.106513. Epub 2022 Oct 14. PMID: 36252772. 4. Guo F, Yan CY. Effect of SecinH3 on lung injury induced by sepsis of rats. Asian Pac J Trop Med. 2015 Dec;8(12):1049-1054. doi: 10.1016/j.apjtm.2015.11.004. Epub 2015 Nov 14. PMID: 26706678.
In vitro protocol:
1. Ren WX, Guo H, Lin SY, Chen SY, Long YY, Xu LY, Wu D, Cao YL, Qu J, Yang BL, Xu HP, Li H, Yu YL, Zhang AY, Wang S, Zhang YC, Zhou KS, Chen ZC, Li QB. Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199. Acta Pharmacol Sin. 2023 Aug 29. doi: 10.1038/s41401-023-01142-2. Epub ahead of print. PMID: 37644132. 2. Hu W, Liu X, Wang S, Sun G, Zhao R, Lu H. SecinH3 Attenuates TDP-43 p.Q331K-Induced Neuronal Toxicity by Suppressing Endoplasmic Reticulum Stress and Enhancing Autophagic Flux. IUBMB Life. 2019 Feb;71(2):192-199. doi: 10.1002/iub.1951. Epub 2018 Oct 30. PMID: 30376609.
In vivo protocol:
1. Dong Y, Song K, Wang P, Guo J, Kang H, Tan X, Zhu B, Peng R, Zhu M, Yu K, Guo Q, Guan H, Li F. Blocking the cytohesin-2/ARF1 axis by SecinH3 ameliorates osteoclast-induced bone loss via attenuating JNK-mediated IRE1 endoribonuclease activity. Pharmacol Res. 2022 Nov;185:106513. doi: 10.1016/j.phrs.2022.106513. Epub 2022 Oct 14. PMID: 36252772. 2. Guo F, Yan CY. Effect of SecinH3 on lung injury induced by sepsis of rats. Asian Pac J Trop Med. 2015 Dec;8(12):1049-1054. doi: 10.1016/j.apjtm.2015.11.004. Epub 2015 Nov 14. PMID: 26706678.
1: Miyata W, Sakaibara N, Yoshinaga K, Honjo A, Takahashi M, Ooki T, Yako H, Sango K, Miyamoto Y, Yamauchi J. Bcl2l12, a novel protein interacting with Arf6, triggers Schwann cell differentiation program. J Biochem. 2024 Nov 7:mvae078. doi: 10.1093/jb/mvae078. Epub ahead of print. PMID: 39510036. 2: Li Y, Li X, Yang Y, Li F, Chen Q, Zhao Z, Zhang N, Li H. Hepatocyte growth factor attenuates high glucose-disturbed mitochondrial dynamics in podocytes by decreasing ARF6-dependent DRP1 translocation. Biochim Biophys Acta Mol Cell Res. 2024 Jan;1871(1):119623. doi: 10.1016/j.bbamcr.2023.119623. Epub 2023 Oct 31. PMID: 37913847. 3: Truong TTK, Fujii S, Nagano R, Hasegawa K, Kokura M, Chiba Y, Yoshizaki K, Fukumoto S, Kiyoshima T. Arl4c is involved in tooth germ development through osteoblastic/ameloblastic differentiation. Biochem Biophys Res Commun. 2023 Oct 30;679:167-174. doi: 10.1016/j.bbrc.2023.09.014. Epub 2023 Sep 7. PMID: 37703759. 4: Ren WX, Guo H, Lin SY, Chen SY, Long YY, Xu LY, Wu D, Cao YL, Qu J, Yang BL, Xu HP, Li H, Yu YL, Zhang AY, Wang S, Zhang YC, Zhou KS, Chen ZC, Li QB. Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199. Acta Pharmacol Sin. 2024 Jan;45(1):180-192. doi: 10.1038/s41401-023-01142-2. Epub 2023 Aug 29. PMID: 37644132; PMCID: PMC10770340. 5: Dong Y, Song K, Wang P, Guo J, Kang H, Tan X, Zhu B, Peng R, Zhu M, Yu K, Guo Q, Guan H, Li F. Blocking the cytohesin-2/ARF1 axis by SecinH3 ameliorates osteoclast-induced bone loss via attenuating JNK-mediated IRE1 endoribonuclease activity. Pharmacol Res. 2022 Nov;185:106513. doi: 10.1016/j.phrs.2022.106513. Epub 2022 Oct 14. PMID: 36252772. 6: Ito A, Fukaya M, Okamoto H, Sakagami H. Physiological and Pathological Roles of the Cytohesin Family in Neurons. Int J Mol Sci. 2022 May 3;23(9):5087. doi: 10.3390/ijms23095087. PMID: 35563476; PMCID: PMC9104363. 7: Yi C, Cai C, Cheng Z, Zhao Y, Yang X, Wu Y, Wang X, Jin Z, Xiang Y, Jin M, Han L, Zhang A. Genome-wide CRISPR-Cas9 screening identifies the CYTH2 host gene as a potential therapeutic target of influenza viral infection. Cell Rep. 2022 Mar 29;38(13):110559. doi: 10.1016/j.celrep.2022.110559. PMID: 35354039. 8: Lee S, Ishitsuka A, Kuroki T, Lin YH, Shibuya A, Hongu T, Funakoshi Y, Kanaho Y, Nagata K, Kawaguchi A. Arf6 exacerbates allergic asthma through cell-to-cell transmission of ASC inflammasomes. JCI Insight. 2021 Aug 23;6(16):e139190. doi: 10.1172/jci.insight.139190. PMID: 34423792; PMCID: PMC8410019. 9: Ito A, Fukaya M, Sugawara T, Hara Y, Okamoto H, Yamauchi J, Sakagami H. Cytohesin-2 mediates group I metabotropic glutamate receptor-dependent mechanical allodynia through the activation of ADP ribosylation factor 6 in the spinal cord. Neurobiol Dis. 2021 Nov;159:105466. doi: 10.1016/j.nbd.2021.105466. Epub 2021 Aug 12. PMID: 34390832. 10: Swart T, Khan FD, Ntlantsana A, Laming D, Veale CGL, Przyborski JM, Edkins AL, Hoppe HC. Detection of the in vitro modulation of Plasmodium falciparum Arf1 by Sec7 and ArfGAP domains using a colorimetric plate-based assay. Sci Rep. 2020 Mar 6;10(1):4193. doi: 10.1038/s41598-020-61101-3. PMID: 32144363; PMCID: PMC7061341. 11: Che G, Gao H, Hu Q, Xie H, Zhang Y. Angiotensin II promotes podocyte injury by activating Arf6-Erk1/2-Nox4 signaling pathway. PLoS One. 2020 Mar 2;15(3):e0229747. doi: 10.1371/journal.pone.0229747. PMID: 32119711; PMCID: PMC7051060. 12: Ren C, Yuan Q, Jian X, Randazzo PA, Tang W, Wu D. Small GTPase ARF6 Is a Coincidence-Detection Code for RPH3A Polarization in Neutrophil Polarization. J Immunol. 2020 Feb 15;204(4):1012-1021. doi: 10.4049/jimmunol.1901080. Epub 2020 Jan 10. PMID: 31924649; PMCID: PMC6994837. 13: Abdul-Salam VB, Russomanno G, Chien-Nien C, Mahomed AS, Yates LA, Wilkins MR, Zhao L, Gierula M, Dubois O, Schaeper U, Endruschat J, Wojciak-Stothard B. CLIC4/Arf6 Pathway. Circ Res. 2019 Jan 4;124(1):52-65. doi: 10.1161/CIRCRESAHA.118.313705. PMID: 30582444; PMCID: PMC6325770. 14: Hu W, Liu X, Wang S, Sun G, Zhao R, Lu H. SecinH3 Attenuates TDP-43 p.Q331K-Induced Neuronal Toxicity by Suppressing Endoplasmic Reticulum Stress and Enhancing Autophagic Flux. IUBMB Life. 2019 Feb;71(2):192-199. doi: 10.1002/iub.1951. Epub 2018 Oct 30. PMID: 30376609. 15: Finicle BT, Ramirez MU, Liu G, Selwan EM, McCracken AN, Yu J, Joo Y, Nguyen J, Ou K, Roy SG, Mendoza VD, Corrales DV, Edinger AL. Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6. J Cell Sci. 2018 Jun 25;131(12):jcs213314. doi: 10.1242/jcs.213314. PMID: 29848659; PMCID: PMC6031383. 16: Charles R, Bourmoum M, Claing A. ARF GTPases control phenotypic switching of vascular smooth muscle cells through the regulation of actin function and actin dependent gene expression. Cell Signal. 2018 Jun;46:64-75. doi: 10.1016/j.cellsig.2018.02.012. Epub 2018 Feb 27. PMID: 29499306. 17: Chakraborti S, Sarkar J, Bhuyan R, Chakraborti T. Role of catechins on ET-1-induced stimulation of PLD and NADPH oxidase activities in pulmonary smooth muscle cells: determination of the probable mechanism by molecular docking studies. Biochem Cell Biol. 2018 Aug;96(4):417-432. doi: 10.1139/bcb-2017-0179. Epub 2017 Dec 5. PMID: 29206487. 18: Ventura S. Toward better treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia? Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F138-F139. doi: 10.1152/ajprenal.00453.2017. Epub 2017 Oct 4. PMID: 28978537. 19: Benabdi S, Peurois F, Nawrotek A, Chikireddy J, Cañeque T, Yamori T, Shiina I, Ohashi Y, Dan S, Rodriguez R, Cherfils J, Zeghouf M. Family-wide Analysis of the Inhibition of Arf Guanine Nucleotide Exchange Factors with Small Molecules: Evidence of Unique Inhibitory Profiles. Biochemistry. 2017 Sep 26;56(38):5125-5133. doi: 10.1021/acs.biochem.7b00706. Epub 2017 Sep 13. PMID: 28858527. 20: Herlemann A, Keller P, Schott M, Tamalunas A, Ciotkowska A, Rutz B, Wang Y, Yu Q, Waidelich R, Strittmatter F, Stief CG, Gratzke C, Hennenberg M. Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate. Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F47-F57. doi: 10.1152/ajprenal.00125.2017. Epub 2017 Aug 30. PMID: 28855187.

View History

Stauffer N-2230

Stauffer N-2230